Annual Report to shareholders
Released
Released
Announcement PDF
ANNUAL REPORT
30 JUNE 2019
RACE ONCOLOGY LIMITED
ACN 149 318 749
ANNUAL REPORT 30 JUNE 2019
Table of Contents
Corporate Directory ........................................................................................................................................................ 1
Directors' Report ............................................................................................................................................................ 2
Remuneration Report (Audited) ..................................................................................................................................... 9
Auditor’s Independence Declaration ............................................................................................................................ 17
Consolidated Statement of Profit or Loss and Other Comprehensive Income ............................................................. 18
Consolidated Statement of Financial Position .............................................................................................................. 19
Consolidated Statement of Changes In Equity............................................................................................................. 20
Consolidated Statement of Cash Flows ....................................................................................................................... 21
Notes to the Financial Statements ............................................................................................................................... 22
Directors' Declaration ................................................................................................................................................... 44
Independent Auditors Report ....................................................................................................................................... 45
Corporate Governance Statement ............................................................................................................................... 50
ASX Additional Information .......................................................................................................................................... 56
Corporate Directory
Directors
Peter Molloy – Managing Director
William Garner – Non Executive Chairman
Chris Ntoumenopoulos – Non Executive Director
John Cullity – Non Executive Director
Company Secretary
Peter Webse
Registered office
Level 40, 140 William Street
Melbourne VIC 3000
Ph: +3 9097 1656
Website: www.raceoncology.com
Auditor
Bentleys Audit & Corporate (WA) Pty Ltd
216 St Georges Terrace
PERTH WA 6000
Share Registry
Automic Registry Services
Level 2
267 St Georges Terrace
Perth WA 6000
Ph: + 8 9324 2099
Securities Exchange Listing
Australian Securities Exchange Limited
Level 40, Central Park 152-158 St Georges Terrace
Perth, WA, 6000
ASX Code – RAC
1
RACE ONCOLOGY LIMITED
ACN 149 318 749
ANNUAL REPORT 30 JUNE 2019
DIRECTORS’ REPORT
Your Directors present their report, together with the financial statements of Race Oncology Limited (“the Company” or “RAC”)
for the financial year ended 30 June 2019.
Information on Directors
Directors have been in office since the start of the financial year to the date of this report unless otherwise stated.
Peter Molloy
—
Managing Director (appointed 1 July 2016)
Qualifications
—
Experience
—
Bachelor of Science (Microbiology and Biochemistry), University of Melbourne
Master of Business Administration, University of Adelaide
Mr. Molloy worked in the pharmaceutical industry for 18 years. At the Australian
pharmaceutical company, Faulding, he managed several Faulding subsidiaries, before
joining Pharmacia (now Pfizer) as Managing Director of its Australia and NZ operations
and later as Vice President of Strategic Marketing for Asia-Pacific and Latin America.
Subsequently, he served as CEO of three biotechnology companies – Biota Holdings Ltd,
SLIL Biomedical Corp and Florigene Ltd – where he managed numerous R&D programs,
raised substantial equity funding and executed four pharmaceutical partnerships. During
his tenure as CEO of the ASX-listed company, Biota Holdings Ltd, the company’s market
value grew from approximately $30m to nearly $300m in three and a half years.
Previously, as CEO of the US company, SLIL Biomedical Corp, he managed R&D and
licensing for the company’s oncology drug development program. Between 2008 and
2014, he was a non-executive director of immune-oncology company, Viralytics
(ASX:VLA). During his career, he has managed seven biotechnology or pharmaceutical
businesses, launched 23 pharmaceutical products, and executed 40 international
licensing or distribution deals.
Interest in Shares and Options
—
4,305,004 ordinary shares, including 4,000,000 loan shares
—
6,000,000 options expiring on 1 July 2021 exercisable at $0.25
Directorships held in listed entities
—
None
William Garner
—
Non-Executive Chairman (appointed 1 July 2016)
Qualifications
—
Master of Public Health, Harvard University
Doctor of Medicine, New York Medical College
William Garner, MD is a US physician, investor, and entrepreneur. Dr Garner is one of the
inventors on the Bisantrene patents, originally filed by Update Pharma, Inc. and now
owned by Race Oncology. Previously, he founded EGB Advisors LLC, a life sciences
advisory firm whose clients have included the M.D. Anderson Cancer Center, the
Kauffman Foundation, ChemGenex (ASX:CXS) and CoTherix. He also founded Inverseon,
Inc., which was merged with the ASX-listed company cBio to create Invion Ltd, serving as
CEO until May of 2013. He founded Urigen Pharmaceuticals, Inc. and co-founded DelMar
Pharmaceuticals, Inc. (NASDAQ:DMPI). Previously, he was at Hoffmann La Roche in
oncology medical affairs and worked as a merchant banker in New York City.
Dr Garner currently serves as Chairman of InMed Pharmaceuticals (TSX:IN) & Isla
Pharmaceuticals and works with several of the other portfolio companies of EGB
Ventures. Dr Garner has a Master of Public Health from Harvard and received his MD
degree from New York Medical College. Dr. Garner did residency training in Anatomic
Pathology at Columbia-Presbyterian and is currently a licensed physician in the State of
New York.
Experience
—
Interest in Shares and Options
—
16,414,927 ordinary shares
Directorships held in listed entities
—
Chairman of listed company InMed Pharmaceuticals (TSX:IN)
2
RACE ONCOLOGY LIMITED
ACN 149 318 749
ANNUAL REPORT 30 JUNE 2019
DIRECTORS’ REPORT
Chris Ntoumenopoulos
—
Non-Executive Director (appointed 27 April 2016)
Qualifications
—
Bachelor of Commerce, majoring in Money and Banking, Investment Finance and
Electronic Commerce
Experience
—
Mr Ntoumenopoulos is Managing Director at Twenty 1 Corporate, a boutique corporate
advisory firm. He has worked in financial markets for the past 12 years, focusing on
Capital Raisings, Portfolio Management and Corporate Advisory. Mr Ntoumenopoulos
has advised and funded numerous ASX companies from early stage venture capital,
through to IPO. He is also a director of various private and public companies which span
across finance, technology and medical sectors.
Interest in Shares and Options
—
660,097 ordinary shares
—
1,000,000 options expiring on 22 November 2019 exercisable at $0.49 and 1,000,000
expiring on 22 November 2019 exercisable at $0.65
—
ResApp Health Limited
—
Ookami Limited (resigned November 2015)
John Cullity
—
Non-Executive Director (appointed 6 April 2018)
Qualifications
—
MBBS, MRCP, MSc(Econs), MBA
Experience
—
John is Managing Director at BioSynergy Partners, a New York and Melbourne based
Directorships held in listed entities
advisory recently spun out of Torreya – the renowned life sciences investment bank. He
additionally, services on the Boards of several life sciences companies including
Ceramedix (seeded by Torreya) and Race Oncology listed on ASX. He resides in New York.
At Torreya, John provided strategic advisory on Mergers & Acquisitions, Partnering and
Financing to life-science companies worldwide. Prior to joining Torreya, he was a senior
member of the Business Development team at Sanofi Pharmaceuticals, where he led
buy side transactions in oncology and diabetes. Earlier in his career, John was Head of
Strategic Pricing & Reimbursement at Sanofi, Director of Health Economics at ScheringPlough, and Consultant at A.T. Kearney. He has also worked at The World Bank and the
World Health Organization.
John graduated in Medicine and sub-specialised in haematology-oncology at QE II
Medical Centre, Perth. He holds a Bachelor of Medicine, Bachelor of Surgery from The
University of Western Australia; Membership of the Royal College of Physicians; Masters
in Health Economics from London School of Economics & Political Science, and MBA
from The Wharton School, University of Pennsylvania.
Interest in Shares and Options
—
2,000,000 options expiring on 27 November 2021 excisable at $0.23
Directorships held in listed entities
—
None
Peter Webse
—
Company Secretary (appointed 5 May 2016)
Qualifications
—
B.Bus, FGIA, FCIS, FCPA, MAICD.
Experience
—
Mr Webse has over 27 years' company secretarial experience and is the managing director
of Platinum Corporate Secretariat Pty Ltd, a company specialising in providing company
secretarial, corporate governance and corporate advisory services.
Company Secretary
3
RACE ONCOLOGY LIMITED
ACN 149 318 749
ANNUAL REPORT 30 JUNE 2019
DIRECTORS’ REPORT
Meeting of Directors
During the financial year 10 meetings of Directors were held. Attendances by each Director during the year are stated in the
following table.
DIRECTORS’
MEETINGS
Number eligible to attend
Number Attended
Peter Molloy
10
10
William Garner
10
10
Chris Ntoumenopoulos
10
10
John Cullity
10
9
Principal Activities
Race Oncology is an Australian speciality pharmaceutical company whose business model is to pursue and bring to market later
stage assets, principally in the cancer field.
The Company’s first important asset is a chemotherapy drug, called Bisantrene, which was the subject of more than 40 phase II
clinical studies, before it was lost in a series of pharmaceutical mergers during the 1990s. Race Oncology is rediscovering
Bisantrene. Race Oncology owns recent patent filings on Bisantrene and has secured Orphan Drug Designation in the US. The
Company’s goal is to complete final development of Bisantrene and bring this valuable cancer drug to market, initially for the
treatment of Acute Myeloid Leukaemia (AML).
Operating Results
The operating loss after income tax amounted to $3,659,402 (2018: $6,306,446 loss); net cash used in operating activities was
$2,674,002 (2018: $3,869,392).
Dividends Paid or Recommended
No dividends were paid or are payable for the financial year.
Review of Operations
On 16 July 2018, Race announced that the FDA had granted Bisantrene a Rare Paediatric Disease (RPD) designation for treatment
of childhood AML (Acute Myeloid Leukaemia). This designation means Bisantrene has the opportunity to be awarded a Priority
Review Voucher (PRV) at the time of marketing approval for childhood AML. The voucher, if awarded, provides rights to a fasttrack FDA review which can be sold to other pharmaceutical companies. The value of the RPD and the potential for the PRV was
additive to the value of the current FDA approval program, which is aimed at adult AML.
On 23 August 2018, Race announced the termination of its representation agreement with CarthaGenetics and the consulting
agreement with Gordon Beck, formerly head of business development for Race. The Company also advised that Dr John Rothman
would step down from his role as full-time Chief Scientific Officer for Race and continue on a part-time basis until the end of
December 2018; subsequently, Dr Rothman agreed to continue providing some informal consulting services to the Company
beyond December to assist with the IND (Investigational New Drug application).
On 17 September 2018, Race announced it had executed an agreement with NSF Health Sciences (NSF) in Washington DC to
facilitate its IND filing in the US for Bisantrene. During the year, NSF acted as the US Agent for Race Oncology with the FDA, serving
as Race’s interface with the FDA regarding agency correspondence, IND amendments, protocol amendments, pharmacovigilance
and other reporting.
On 27-29 September 2018, Race attended and sponsored the first annual meeting of the International Academy for Clinical
Haematology (IACH) in Paris. It was an important opportunity to increase Race’s recognition and reputation with international
haematological oncologists and to discuss clinical plans and NPP opportunities for Bisantrene. One of speakers and session chairs
was Professor Borje Andersson, with whom the Company subsequently signed a consulting agreement (announced 22 January
4
RACE ONCOLOGY LIMITED
ACN 149 318 749
ANNUAL REPORT 30 JUNE 2019
DIRECTORS’ REPORT
2019). Race also met Professor Arnon Nagler from Israel, who subsequently agreed to undertake a trial of Bisantrene in adult AML
(announced 14 May 2019).
On 1 October 2018, Race announced an agreement with Mr Tom Lee of Houston, Texas. The agreement provided for Mr Lee to
assist the Company with partnering, funding and clinical trial partnering opportunities in the US, particularly in Houston. One
important focus for Mr Lee was to make introductions to opinion leaders and clinical trial groups at MD Anderson Cancer Center
(MDACC), with a focus on funding and conducting a paediatric trial of Bisantrene in support of the RPD designation.
On 1 November 2018, Race announced an agreement with Biosynergy Partners LLC (Biosynergy) to pursue transactions around
Bisantrene. Biosynergy is a transaction consulting business owned by Dr John Cullity, a New York-based transaction consultant
and a non-executive director of RAC. Under the Agreement, potential transactions included a sale, license, partnership,
collaborative venture or other arrangement, whereby an interest in Bisantrene is transferred to a third party. During the year, the
Company actively worked with Dr Cullity to identify and engage with potential partners..
On 17 December 2018, Race announced that it had executed an agreement with TrueMed for distribution and sales of Bisantrene
in Israel, under a Named Patient Program (NPP). Under the agreement, Race and TrueMed shares the value of all Bisantrene NPP
sales in Israel, with 60% of sales turnover paid to Race and 40% retained by TrueMed. TrueMed will be responsible for gaining the
approval of the Israeli Ministry of Health (IMOH) for local NPP distribution of Bisantrene, and sales cannot commence until that
approval has been obtained. The agreement will operate for an initial period of three years, after which, it can be terminated with
nine months’ notice by either party.
During the year, the Company continued to seek Named Patient Program (NPP) usage in Europe, but without any demonstrable
success, in terms of sales. In late September 2018, the Company was advised by a UK hospital that the hospital intended to place
an NPP order for Bisantrene for an AML patient who had failed other treatments; the order was received by Durbin, Race’s agent
in the UK, but unfortunately, the patient rapidly progressed and died before the order could be filled. Race remains committed to
achieving contemporary usage of Bisantrene by clinicians, either under NPP or via investigator-initiated trials. During the year, Dr
Samar Al-Behaisi, Race’s Chief Medical Officer continued to build relationships with key AML clinicians towards that goal.
On 24 January 2019, Race announced an agreement with Professor Borje Andersson from the M.D. Anderson Cancer Research
Center (MDACC) in Houston, Texas. Under the initial 12-month agreement, Professor Andersson was engaged to advise Race on
clinical protocols for its adult and paediatric AML trials, advise Race on new product development strategies and acquisitions,
assist Race with introductions to AML clinical trial groups at MD Anderson and support MDACC’s participation in Race’s clinical
trials or investigator initiated clinical studies on Bisantrene, and assist Race with introductions to international and US and
international investigators who could participate in Race’s proposed NPP for Bisantrene. Prof. Andersson received compensation
in the form of 420,000 RAC share options, which vested over 12 months.
Prof. Andersson stated: “I found that Race Oncology’s research strategy for developing new therapies for both paediatric and adult
AML are a perfect complement to my own long-standing research interests. Therefore, it is with great excitement and the highest
level of enthusiasm that I look forward to working with the team at Race Oncology.”
On 25 February 2019, Race announced that Dr Roland Walter – a leading international AML expert, based at the Fred Hutchinson
Cancer Research Center in Seattle – had agreed to be the Principal Investigator for the US registration trial for Bisantrene. Trial
commencement is subject to the filing by Race of an IND (Investigational New Drug application) with the FDA and the FDA agreeing
to the IND.
On 25 March 2019, Race announced that it had filed the IND with the US FDA, on schedule. The IND application was considered
an important milestone for the Company, involving around 2,000 pages of documentation on Bisantrene. For the Bisantrene
registration trial to proceed, the IND would need to be allowed by the FDA. On 24 April 2019, Race advised the market that, as
expected, the FDA had a number of questions about the proposed trial and as a result, the trial would be on a ‘clinical hold’ until
the questions were resolved. The Company is continuing to seek to address these questions.
On 14 May 2019, Race announced that it has signed an agreement to conduct an investigator-initiated trial of Bisantrene at the
Sheba Medical Center in Israel. This was considered an important development, as it represented the first use of Bisantrene in
patients since the drug disappeared approximately 25 years ago. The trial is led by Professor Arnon Nagler, who is a highlyregarded international leader in the leukaemia field.
Prof. Nagler stated: “I am excited about the potential for Bisantrene in our leukemic patients in whom the disease is unresponsive
and have very few alternatives. A number of new targeted agents have become available, but these are only useful in the small
percentage of patients who have specific, identifiable mutations.”
The trial is titled “Bisantrene for relapsed/refractory acute myelogenous leukemia (AML)” and its primary objective will be to
generate clinical remissions (CR) in patients with AML, who are resistant to other therapy (refractory), have relapsed after previous
therapy, or cannot receive further anthracycline treatment. The trial is expected to recruit 12 adult subjects over 12 months and
5
RACE ONCOLOGY LIMITED
ACN 149 318 749
ANNUAL REPORT 30 JUNE 2019
DIRECTORS’ REPORT
report CR and a range of secondary endpoints, including leukaemia free survival (LFS) and overall survival (OS). All patients are
expected to receive Bisantrene 250mg/m2/day for 7 days, in conjunction with conventional supportive care.
Shortly after the end of the year, on 25 July 2019, the Company announced that the first patient had been treated in the trial at
the Sheba Medical Center in Israel.
During the year, Race filed a series of ASX notices, reporting changes in Directors’ shareholdings, especially in relation to Dr William
Garner, the Company’s chairman. Most of the notices related to internal redistribution of shares held in the Company by Update
Pharma, Inc. (Update), to the shareholders of Update, the major shareholder being Dr Garner. Update is the US entity that
provided the Bisantrene IP to form Race Oncology.
In addition, on 21 December 2018 and 12 July 2019, Race filed Appendix 3Bs advising the conversion of performance shares into
ordinary shares by Update, with 5 million converted at each date. The performance share milestones were met in June 2018 and
were announced to the market on 2 July 2018 (“Performance Shares Milestones Met”). As indicated in that announcement there
was a provision for Update to elect to receive the performance shares (at a time of their choosing), which was reflected in the
December 2018 and July 2019 Appendix 3Bs.
Outlook
Race remains committed to achieving contemporary usage of Bisantrene by clinicians; in that regard, we look forward to further
results of the Sheba Medical Center trial and hope to start other investigator-initiated trials of Bisantrene. Race believes that
gaining contemporary clinician experience may pave the way for future NPP sales.
The US IND is currently on clinical hold, pending Race’s responses to questions from the FDA. The pathway forward for Race likely
involves further testing to generate new data and changes to the trial protocol, in order to meet the FDA’s demands. This would
be followed by a ‘Type C’ meeting with the FDA to discuss the additional data and the trial protocol. Because of the cost
commitment associated with this additional testing and the Type C process, Race is deferring activity on the IND until additional
funding is secured during FY20.
In the meantime, the paediatric AML program and the potential to secure a valuable Priority Review Voucher (PRV) remain a
major value-creating opportunity for Race. The Company is actively exploring ways in which the necessary clinical work to support
this program and the PRV can be conducted.
The Company continues to believe in the value of Bisantrene. The positive comments cited here by Professors Andersson and
Nagler are reflective of much of the positive feedback we have received from AML clinicians over the last three years. There is
little doubt that Bisantrene has a role to play in treating AML; and the fact that an international AML leader, such as Professor
Nagler, is prepared to use Bisantrene on his relapsed/refractory AML patients is a clear indication of this. Over the coming year,
we hope to see the trial in Israel prompt other investigators in other countries to undertake their own investigator-sponsored
trials of Bisantrene and through this process, generate a growing awareness of Bisantrene’s value.
Financial Position
The net assets of the Company at 30 June 2019 were $5,049,906 (2018: $7,930,697), including $0.99 million in cash. Excluding
non-cash items, such as share-based payments and amortisation expense, the total operational expenditure for the year was
$2.81 million, which was a 31% reduction from the previous year ($4.06 million), with the largest savings being in business
development and marketing (-$0.65 million) and R&D (-$0.33 million); however, savings were also achieved in manufacturing &
distribution, corporate advice, and travel costs. In addition, R&D tax credit income increased to $0.23 million (2018: $0.17 million).
Based on the costs savings and consequently, the overall lower cost structure going forward, the Company expects significantly
reduced expenses overall during 2020 financial year.
Significant Events after the Reporting date
On 12 July 2019, the Company issued 5,000,000 fully paid ordinary shares following the conversion of Milestone (ii) Performance
Shares. All of the Companies Performance Shares have now been converted into ordinary shares.
On 25 July 2019, the Company announced that the first patient had been treated with Race’s cancer drug, Bisantrene, in the trial
at the Sheba Medical Center in Israel. Race was advised by the Sheba Medical Center that the first relapsed/refractory AML patient
had been recruited into the trial and completed their seven-day course treatment with Bisantrene, without any major
complications.
6
RACE ONCOLOGY LIMITED
ACN 149 318 749
ANNUAL REPORT 30 JUNE 2019
DIRECTORS’ REPORT
On 13 August 2019, the Company announced it had secured a new patent on its cancer drug, Bisantrene, from the United States
Patent and Trademarks Office. This is Race’s third patent granted on Bisantrene in the United States. The new patent covers
expanded uses of Bisantrene, in particular its use in combination with other cancer drugs to treat Acute Myeloid Leukaemia and
breast cancer.
On 20 August 2019, the Company announced it had completed a placement of $1.45million, led by prominent biotechnology
investor Dr Daniel Tillett and that it had issued 8,500,000 shares at $0.066 each and 4,250,000 options exercisable at $0.099 and
expiring on 31 August 2021 to date pursuant to that placement.
Future Developments, Prospects and Business Strategies
Our goal continues to be to ensure that Bisantrene’s potential is realised. We will continue to focus our efforts on completing the
IND, supporting investigator-sponsored trials such as the one in Israel, and pursuing opportunities for external funding of the
paediatric program. We hope that these programs will generate valuable milestones in the coming year that will significantly lift
Race’s share price and market value. In the meantime, we have cut overheads, positioning the Company for a significantly lower
cash outflow in FY2020, consistent with our ability to raise funds.
Environmental Regulations
The Company aims to comply with the identified regulatory requirements in each jurisdiction in which it operates. There have
been no known material breaches of the environmental regulations.
Proceedings on Behalf of Company
No person has applied for leave of Court to bring proceedings on behalf of the Company or intervene in any proceedings to which
the Company is a party for the purpose of taking responsibility on behalf of the Company for all or any part of those proceedings.
The Company was not a party to any such proceedings during the year.
Share Options
Unissued shares under option
At the date of this report, the un-issued ordinary shares of Race Oncology Limited under option are as follows:
Grant Date
Expiry Date
Exercise Price
Number of shares
under option
1 July 2016
1 July 2021
$0.25
9,000,000
22 November 2016
1 August 2021
$0.256
135,000
28 March 2017
1 April 2022
$0.25
1,500,000
8 May 2017
8 May 2022
$0.25
100,000
22 November 2017
22 November 2019
$0.49
2,000,000
22 November 2017
22 November 2019
$0.65
2,000,000
20 June 2018
19 March 2020
$0.45
5,000,000
13 July 2018
16 May 2023
$0.32
1,500,000
13 July 2018
13 January 2020
$0.30
6,000,000
1 October 2018
1 October 2023
$0.12
420,000
27 November 2018
27 November 2021
$0.23
2,000,000
21 January 2019
21 January 2024
$0.12
420,000
13 March 2019
12 March 2024
$0.10
500,000
13 March 2019
12 March 2024
$0.135
100,000
31 May 2019
31 May 2024
$0.085
420,000
31 May 2019
31 May 2024
$0.085
420,000
31,515,000
Option holders do not have any right, by virtue of the option, to participate in any share issue of the Company or any related body
corporate.
7
RACE ONCOLOGY LIMITED
ACN 149 318 749
ANNUAL REPORT 30 JUNE 2019
DIRECTORS’ REPORT
Indemnification and Insurance of Directors and Officers
The Company indemnifies each of its Directors, Officers and Company Secretary. The Company indemnifies each Director or
Officer to the maximum extent permitted by the Corporations Act 2001 from liability to third parties, except where the liability
arises out of conduct involving lack of good faith, and in defending legal and administrative proceedings and applications for such
proceedings.
The Company must use its best endeavours to insure a Director or Officer against any liability, which does not arise out of conduct
constituting a wilful breach of duty or a contravention of the Corporations Act 2001. The Company must also use its best
endeavours to insure a Director or Officer against liability for costs and expenses incurred in defending proceedings whether civil
or criminal.
The Company has not entered into any agreement with its current auditors indemnifying them against any claims by third parties
arising from their report on the financial report.
During the year the Company paid insurance premiums to insure directors and officers against certain liabilities arising out of
their conduct while acting as an officer of the Group. Under the terms and conditions of the insurance contract, the nature of
the liabilities insured against and the premium paid cannot be disclosed.
Non-audit services
Details of amounts paid or payable to the auditor for non-audit service provided during the year is outlined in Note 5 to the
financial statements.
The Board of Directors is satisfied that the provision of non-audit services during the year is compatible with the general standard
of independence for auditors imposed by the Corporations Act 2001.
The Directors are of the opinion that the service as disclosed in Note 5 to the financial statements do not compromise the external
auditor’s independence, based on resolution of the directors, for the following reasons:
•
All non-audit services have been reviewed and approved to ensure that they do not impact integrity and objectivity of
the auditor; and
•
None of the services undermine the general principles relating to auditor independence set out in APES 110 “Code of
Ethics for Professional Accountants’ issued by the Accounting Professional & Ethical Standards Board, including
reviewing or auditing the auditor’s own work, acting in a management or decision-making capacity of the Company,
acting as advocate for the Company or jointly sharing economic risks and rewards.
Auditor’s Independence Declaration
The auditor’s independence declaration for the year ended 30 June 2019 has been received and can be found on page 17.
8
RACE ONCOLOGY LIMITED
ACN 149 318 749
ANNUAL REPORT 30 JUNE 2019
DIRECTORS’ REPORT
REMUNERATION REPORT (AUDITED)
This remuneration report for the year ended 30 June 2019 outlines the remuneration arrangements of the Company i
Share your feedback
Discover